New Zealand markets close in 3 hours 36 minutes
  • NZX 50

    11,293.23
    +86.30 (+0.77%)
     
  • NZD/USD

    0.6386
    +0.0003 (+0.05%)
     
  • NZD/EUR

    0.6035
    +0.0011 (+0.18%)
     
  • ALL ORDS

    7,360.10
    +56.80 (+0.78%)
     
  • ASX 200

    7,121.00
    +56.50 (+0.80%)
     
  • OIL

    111.03
    -1.18 (-1.05%)
     
  • GOLD

    1,838.60
    -2.60 (-0.14%)
     
  • NASDAQ

    11,875.63
    -52.69 (-0.44%)
     
  • FTSE

    7,302.74
    -135.35 (-1.82%)
     
  • Dow Jones

    31,253.13
    -236.94 (-0.75%)
     
  • DAX

    13,882.30
    -125.46 (-0.90%)
     
  • Hang Seng

    20,120.68
    0.00 (0.00%)
     
  • NIKKEI 225

    26,472.55
    +69.71 (+0.26%)
     
  • NZD/JPY

    81.6120
    +0.0960 (+0.12%)
     

ImmunoPrecise Antibodies Announces Grant of Stock Options

·1-min read

VICTORIA, British Columbia, January 11, 2022--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that on January 7, 2022 its board of directors approved the grant of 170,000 stock options (the "Options") under its stock option plan to acquire up to an aggregate of 170,000 common shares in the capital of IPA ("Common Shares"). The Options were granted to certain officers of IPA. Each Option is exercisable for a period of five years from the date of grant at an exercise price of Cdn $7.94 per Common Share. One third of the Options granted to each officer will vest every six months from the date of grant.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005779/en/

Contacts

LifeSci Advisors
John Mullaly
Email: jmullaly@lifesciadvisors.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting